ReviewClinical and experimental rheumatology2025

Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases.

Flavia V Castelino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.